Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.

Pasquale AgostiPasqualina De LeoMarco CapecchiBarbara FerrariIlaria ManciniSalvatore GattilloSilvia Maria TrisoliniErminia RinaldiGian Marco PoddaLucia PreziosoPrassede SalutariLuca FacchiniDomenica CaramazzaGiulia TolomelliAndrea ArtoniFlora Peyvandi

Published in: Research and practice in thrombosis and haemostasis (2023)

•Data on caplacizumab use for thrombotic thrombocytopenic purpura (TTP) in Italy are missing.•Twenty-six Italian patients were treated with caplacizumab for an acute immune TTP episode.•Caplacizumab was effective in treating acute TTP in the Italian real-world clinical setting.•Two major bleeds leading to drug discontinuation were observed.

Keyphrases

liver failure
end stage renal disease
newly diagnosed
respiratory failure
drug induced
chronic kidney disease
aortic dissection
prognostic factors
emergency department
machine learning
intensive care unit
patient reported outcomes
data analysis